Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated corporate presentation issued August 3, 2026 for investor and analyst meetings.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation issued August 3, 2026 for investor and analyst meetings
- Presentation available on Keros’ website and filed as Exhibit 99.1
- Reg FD disclosure furnished, not formally filed under Exchange Act Section 18
- Exhibit not incorporated into other SEC filings unless expressly referenced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.